NaglaFawzyAbdel KarimMD

Professor, Internal Medicine, Division of Hematology/Oncology-Augusta University-Georgia Cancer Center

Dr. Abdel Karim is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
8081 Innovation Park Dr
Fairfax, VA 22031
Phone+1 571-472-4724

Fax+1 571-472-0241

University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2009
Cleveland Clinic Foundation/Fairview HospitalResidency, Internal Medicine, 2003 - 2006
Cairo University School of MedicineClass of 1993

PubMed

53 citations
Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review.
Samiha Mohsen, Philip T Sobash, Ghada Fahad Algwaiz, Noor Nasef, Safaa Abed Al-Zeidaneen
Current Oncology. 2022-03-05
15 citations
Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience.
Vidhya Karivedu, Ihab Eldessouki, Ahmad Taftaf, Zheng Zhu, Abouelmagd Makramalla
Case Reports in Oncological Medicine. 2019-04-17
69 citations
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.
Julia Judd, Nagla Abdel Karim, Hina Khan, Abdul Rafeh Naqash, Yasmine Baca
Molecular Cancer Therapeutics. 2021-09-13

Lectures

Phase I trial of chloroquine (CQ)/hydroxychloroquine (HCQ) in combination with carboplatin-gemcitabine (CG) in patients with advanced solid tumors.
2019 ASCO Annual Meeting - 6/1/2019
Correlation between K-RAS mutant subsets, TP53 mutation, and PD-L1 status in non-small cell lung cancer (NSCLC).
2019 ASCO Annual Meeting - 6/1/2019